Projects

CANDLE will play a strategic role in supporting the European Health Data Space (EHDS) by establishing a federated network of national nodes in the cancer domain. These nodes can be seen as demonstrators for national disease-specific implementation of the EHDS, aligning EU-wide health data policies with regional and national requirements. Furthermore, CANDLE puts into practice the EU Mission on Cancer and Europe’s Beating Cancer Plan by supporting their implementation on national level and fostering dialogue with other major initiatives.

The canSERV project aims to defragment the landscape of European cancer research and will enable academia and industry access to cross-cutting services and support from basic science up to clinical translation to foster personalised medicine for cancer patients. The project will contribute to the EU Cancer Mission through the provision of innovative services.

CoMeCT is ensuring enhanced European clinical research preparedness and response capacity to infectious disease (ID) outbreaks with epidemic potential through sustained strategic and scientific coordination of adaptive platform trials and cohort studies. Uniting existing coordination initiatives into a single coherent coordination mechanism for adaptive platform trials and cohort studies.

The ECRAID-Base (European Clinical Research Alliance for Infectious Diseases) project follows the successful ECRAID-Plan project which defined the business model of the ECRAID network. This pan-European network will generate rigorous evidence to improve diagnosis, prevention and treatment of infections and to better respond to emerging infectious disease threats.

ECRAID-PRIME, a European Adaptive Platform Trial (APT) of COVID-19 therapeutics in primary care will build on many years of EU investment in infrastructure for primary care trials and a mature primary care research network that has pioneered novel, efficient, platform clinical trial designs.

The central aim of the project is to enable clinical and quality of care assessment research using data extracted directly from electronic health records (EHR) of emergency departments (ED). 

EOSC-ENTRUST aims to create a European network of Trusted Research Environments (TRE) for sensitive data and to drive European interoperability by joint development of a common blueprint for federated data access and analysis to support the development of the European Open Science Cloud (EOSC).

This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing European public health needs. The EU-funded ERA4Health Partnership brings together 32 entities and 27 funding organisations from 21 countries, with the common goal of fostering high-impact translational research for addressing public health needs.

ERDERA aims to have a major impact on rare diseases by supporting patient driven research to develop new treatments and diagnostic pathways and harnessing the potential of health and research data, Artificial Intelligence (AI) and digital technologies. The partnership will be crucial in helping shape the European Research Area on Rare Diseases.

The ERIC Forum 2 project is intended to strengthen and support the implementation of the ERIC Regulation and ERIC services, to structure their cooperation and sustainability across Europe, and to consolidate the integration of the ERICs into the European Research Area by deepening the ERIC Forum’s contribution to research policies. 

EU-RESPONSE aims to design and run a new adaptive European platform trial on COVID-19 and emerging infectious diseases. EU-RESPONSE will allow the European expansion of the DisCoVeRy study, a phase III, open-label, adaptive, randomized, controlled, multi-centre clinical trial designed to evaluate the safety and efficacy of medicinal products in hospitalized adult patients diagnosed with COVID-19. The DisCoVeRy trial was originally initiated in France as WHO Solidarity trial “add-on” study and thanks to EU-RESPONSE it will further expand to many other European countries.

EuroGCT is here to help make sense of gene and cell therapy - from science in the lab to treatments for patients. The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) brings together 47 partner organisations and institutions across Europe with a goal of providing reliable and accessible information about the use of cells and genetic material to treat disease.

The INTEGRATE-LMedC project aims to develop a new concept to guide and support decision-making for the next-generation research infrastructure (RI) to facilitate efficient utilization and harmonization of large medical cohorts (LMedC), and to accelerate scientific and medical breakthroughs in Europe and beyond.

The overall aim of INVENTS is to provide clinical trial stakeholders, trialists and regulators with a generalisable framework encompassing methods, workflows and evidence-tools to improve the level of evidence in regulatory decision making in rare diseases. This will be achieved through the development and validation of improved extrapolation models, simulation and in silico trials, model based clinical trial design and evidence synthesis methods, all based on robust and mature computational models and qualified on extensive data from representative selected use cases.

QUANTUM aims to develop and implement a label mechanism that will attest to the quality and utility of data as well as the maturity level of the providers' data quality procedures, and which could ideally be adopted as part of future HealthData@EU.

The READI project aims to promote a less fragmented and more democratic ecosystem for clinical studies (CS) by engaging key stakeholders in the process of including underserved and underrepresented populations in CS. The consortium is coordinated by the Servicio Madrileño de Salud (SERMAS), through Hospital Universitario La Paz, as the Project Coordinator, Novartis as the Project Lead, and supported by The Synergist as the Digital & Sustainability Coordinator. This project brings together a highly multidisciplinary consortium of 73 organizations from 18 different countries. The six-year project will have a budget of €66.8 million, of which €31.5 million is requested to be funded by IHI, and €34.2 million is committed by industry and contributing partners.

The project kicks off with the ambition of establishing a European research and innovation eco-system that facilitates fast and cost-effective patient-centric development and access to repurposed medicines.

The aim of SENSITISE is to provide education and training on the importance, conduct and impact of designing clinical trials to ensure appropriate representation of under-served groups. The target audiences are undergraduate biomedical and health professions students, as well as individuals working and researching in the field of clinical trials, including patient and public partners.